Abstract
Background:
We need more effective treatments for refractory non-small cell lung cancer.
Case:
A 61-year-old man had a recurrence in the left ninth rib invading the chestwall 4 years after resection of squamous cell lung cancer. The metastatic lesion grew larger even after 3 different regimens of systemic chemotherapy and local irradiation. Then he started to receive 120 mg of TS-1 daily for 28 days followed by 14 days of rest (1 course). A partial response was achieved after 2 courses of the treatment and continued for 6 weeks. Doses of oxycodone hydrochloride could be reduced to one-sixth of the initial dose according to tumor regression.
Conclusion:
This is the first report to show the effectiveness of TS-1 for a refractory recurrence of lung cancer to the bone.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Administration, Oral
-
Antimetabolites, Antineoplastic / administration & dosage
-
Antimetabolites, Antineoplastic / therapeutic use*
-
Bone Neoplasms / drug therapy*
-
Bone Neoplasms / secondary*
-
Carcinoma, Squamous Cell / drug therapy
-
Carcinoma, Squamous Cell / radiotherapy
-
Carcinoma, Squamous Cell / secondary*
-
Carcinoma, Squamous Cell / surgery
-
Combined Modality Therapy
-
Drug Administration Schedule
-
Drug Combinations
-
Humans
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / pathology*
-
Lung Neoplasms / radiotherapy
-
Lung Neoplasms / surgery
-
Male
-
Middle Aged
-
Oxonic Acid / administration & dosage
-
Oxonic Acid / therapeutic use*
-
Pneumonectomy
-
Postoperative Period
-
Quality of Life
-
Ribs*
-
Tegafur / administration & dosage
-
Tegafur / therapeutic use*
Substances
-
Antimetabolites, Antineoplastic
-
Drug Combinations
-
S 1 (combination)
-
Tegafur
-
Oxonic Acid